Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.56 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.42 |
| ▸ | FEN1 | P39748 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137372 | 0.85 | MET (0.50) | METAXLGCKMAPK14BRAF | |
| SCHEMBL1137206 | 0.84 | MET (0.47) | METALOX5APFEN1BRAFKDR | |
| SCHEMBL1137246 | 0.84 | MET (0.46) | METBRAFKDR | |
| SCHEMBL5176178 | 0.79 | MET (0.59) | METALOX5APFEN1AXL | |
| SCHEMBL29631575 | 0.78 | MET (0.55) | METALOX5APFEN1AXLNOS3 | |
| SCHEMBL1136810 | 0.78 | MET (0.55) | METALOX5APFEN1AXLNOS3 | |
| SCHEMBL28510567 | 0.78 | MET (0.62) | METALOX5APFEN1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL1137241 | 0.76 | MET (0.54) | METALOX5APFEN1AXLNOS3 | |
| SCHEMBL6032672 | 0.76 | MET (0.52) | METALOX5APFEN1AXLNOS3 | |
| SCHEMBL1137330 | 0.76 | MET (0.73) | METAXLBRAFKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459562-B2 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| EP-1737451-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005117867-A2 | MONOCYCLIC HETEROCYCLES AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245530-A1 | Monocyclic heterocycles as kinase inhibitors | CDK2, MAP3K19, CDK1 | MET 162/4885ALOX5AP 4561/4885FEN1 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.